- Home
- DVAX vs BBUC Comparison
DVAX vs BBUC Comparison
Compare DVAX & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- BBUC
- Stock Information
- Founded
- DVAX 1996
- BBUC 2022
- Country
- DVAX United States
- BBUC United States
- Employees
- DVAX N/A
- BBUC N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- BBUC
- Sector
- DVAX Health Care
- BBUC
- Exchange
- DVAX Nasdaq
- BBUC Nasdaq
- Market Cap
- DVAX 1.7B
- BBUC 1.9B
- IPO Year
- DVAX 2004
- BBUC N/A
- Fundamental
- Price
- DVAX $12.90
- BBUC $24.89
- Analyst Decision
- DVAX Buy
- BBUC
- Analyst Count
- DVAX 2
- BBUC 0
- Target Price
- DVAX $22.00
- BBUC N/A
- AVG Volume (30 Days)
- DVAX 1.3M
- BBUC 36.7K
- Earning Date
- DVAX 11-07-2024
- BBUC 01-01-0001
- Dividend Yield
- DVAX N/A
- BBUC 1.00%
- EPS Growth
- DVAX N/A
- BBUC N/A
- EPS
- DVAX 0.15
- BBUC N/A
- Revenue
- DVAX $260,810,000.00
- BBUC $7,945,000,000.00
- Revenue This Year
- DVAX $21.64
- BBUC N/A
- Revenue Next Year
- DVAX $19.81
- BBUC N/A
- P/E Ratio
- DVAX $85.33
- BBUC N/A
- Revenue Growth
- DVAX N/A
- BBUC 56.83
- 52 Week Low
- DVAX $9.74
- BBUC $18.21
- 52 Week High
- DVAX $15.01
- BBUC $28.29
- Technical
- Relative Strength Index (RSI)
- DVAX 57.32
- BBUC 35.73
- Support Level
- DVAX $12.66
- BBUC $25.37
- Resistance Level
- DVAX $13.17
- BBUC $25.97
- Average True Range (ATR)
- DVAX 0.29
- BBUC 0.65
- MACD
- DVAX -0.04
- BBUC -0.31
- Stochastic Oscillator
- DVAX 48.08
- BBUC 0.73
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a global basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.